title: The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention.
abstract: BACKGROUND
  High levels of Pentraxin 3 (PTX3) are reported in acute myocardial infarction (AMI).
  
  
  OBJECTIVE
  To investigate circulating levels and gene expression of PTX3 in patients with AMI and stable angina pectoris (AP) undergoing PCI.
  
  
  METHODS
  Ten patients with AP and 20 patients with AMI were included. Blood samples were drawn before PCI in the AP group and after 3 and 12 hours and days 1, 3, 5, 7, and 14 in both groups.
  
  
  RESULTS
  Circulating PTX3 levels were higher in AMI compared to AP at 3 and 12 hours (P < 0.001 and P = 0.003). Within the AMI group, reduction from 3 hours to all later time points was observed (all P ≤ 0.001). Within the AP group, increase from baseline to 3 hours (P = 0.022), followed by reductions thereafter (all P < 0.05), was observed. PTX3 mRNA increased in the AMI group from 3 hours to days 7 and 14 in a relative manner of 62% and 73%, while a relative reduction from baseline to 3 and 12 hours of 29% and 37% was seen in the AP group.
  
  
  CONCLUSIONS
  High circulating PTX3 levels shortly after PCI in AMI indicate that AMI itself influences PTX3 levels. PTX3 mRNA might be in response to fluctuations in circulating levels.
authors.affiliation: Department of Cardiology, Oslo University Hospital Ullevål, P.O. Box 4956, Nydalen, 0424 Oslo, Norway ; Faculty of Medicine, University of Oslo, P.O. Box 1078, Blindern, 0316 Oslo, Norway.
authors.forename: Ragnhild
authors.identifier: 0000-0001-5012-9214
authors.initials: R
authors.lastname: Helseth
authors.affiliation: Department of Cardiology, Oslo University Hospital Ullevål, P.O. Box 4956, Nydalen, 0424 Oslo, Norway.
authors.forename: Svein
authors.initials: S
authors.lastname: Solheim
authors.affiliation: Department of Cardiology, Oslo University Hospital Ullevål, P.O. Box 4956, Nydalen, 0424 Oslo, Norway ; Faculty of Medicine, University of Oslo, P.O. Box 1078, Blindern, 0316 Oslo, Norway.
authors.forename: Trine
authors.initials: T
authors.lastname: Opstad
authors.affiliation: Section for Interventional Cardiology, Department of Cardiology, Division of Cardiovascular and Pulmonary Diseases, Oslo University Hospital Ullevål, P.O. Box 4956, Nydalen, 0424 Oslo, Norway.
authors.forename: Pavel
authors.identifier: 0000-0003-1287-9174
authors.initials: P
authors.lastname: Hoffmann
authors.affiliation: Department of Cardiology, Oslo University Hospital Ullevål, P.O. Box 4956, Nydalen, 0424 Oslo, Norway ; Faculty of Medicine, University of Oslo, P.O. Box 1078, Blindern, 0316 Oslo, Norway.
authors.forename: Harald
authors.initials: H
authors.lastname: Arnesen
authors.affiliation: Department of Cardiology, Oslo University Hospital Ullevål, P.O. Box 4956, Nydalen, 0424 Oslo, Norway ; Faculty of Medicine, University of Oslo, P.O. Box 1078, Blindern, 0316 Oslo, Norway.
authors.forename: Ingebjørg
authors.initials: I
authors.lastname: Seljeflot
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000097:blood*; D001772:Blood Cell Count; D002097:C-Reactive Protein / Q000378:metabolism*; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007962:Leukocytes / Q000166:cytology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood*; D062645:Percutaneous Coronary Intervention; D012333:RNA, Messenger / Q000378:metabolism; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D013997:Time Factors; D020107:Troponin T / Q000097:blood; D000099153:Pentraxins
chemical_list: D002097:C-Reactive Protein; D012333:RNA, Messenger; D000683:Serum Amyloid P-Component; D020107:Troponin T; D000099153:Pentraxins
references.citation: Cardiovasc Pathol. 2011 Jan-Feb;20(1):e27-35
references.pmid: 20356766
references.citation: Circulation. 2000 Aug 8;102(6):636-41
references.pmid: 10931803
references.citation: J Exp Med. 2007 Apr 16;204(4):793-804
references.pmid: 17389238
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Circulation. 2009 Aug 25;120(8):699-708
references.pmid: 19667236
references.citation: Circulation. 2002 Mar 5;105(9):1135-43
references.pmid: 11877368
references.citation: Arthritis Rheum. 2012 Mar;64(3):854-65
references.pmid: 21989653
references.citation: Eur J Clin Invest. 2012 Jun;42(6):686-91
references.pmid: 22577952
references.citation: J Immunol. 2011 Jul 15;187(2):970-9
references.pmid: 21677138
references.citation: PLoS One. 2012;7(6):e39484
references.pmid: 22761804
references.citation: Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):594-9
references.pmid: 19164811
references.citation: Scand J Clin Lab Invest. 2008;68(7):555-62
references.pmid: 19378426
references.citation: Circulation. 2004 Oct 19;110(16):2349-54
references.pmid: 15477419
references.citation: Mediators Inflamm. 2012;2012:419804
references.pmid: 23125484
references.citation: Circulation. 2008 Feb 26;117(8):1055-64
references.pmid: 18268142
references.citation: Mediators Inflamm. 2012;2012:920517
references.pmid: 22577258